Cordyceps sinensis sold 5 billion in 3 years | It was kicked out of health products by the Food and Drug Administration!

From May 28th to May, the medical network began to enter the harvest season in the country's Cordyceps-growing areas. However, after the previous website of the State Food and Drug Administration, Cordyceps sinensis kicked out health care products, it was known as the “soft gold”. How do big breeds continue to write their myths...

Starting from the end of April each year, starting from Sichuan, the Cordyceps production area all the way to the west, to Yunnan, Qinghai, and Tibet, entered more than two months of shipment.

But this year, Cordyceps suffered the most severe ban in history.

On March 8th, 2018, the website of the former State Food and Drug Administration issued "On stopping the use of Cordyceps sinensis Healthy food Notice of Pilot Work (hereinafter referred to as "Notice").

The “Notice” stated that Cordyceps sinensis is not a dual-purpose substance for medicine and food, and long-term use may harm the human body and cannot be Health products Ways to sell - This is another serious attack after Cordyceps was suspended as a pilot drug for 2016.

The marketization of Cordyceps sinensis has always been accompanied by great controversy.

The former Director of the State Food and Drug Administration, Bi Jingquan, had publicly explained: Cordyceps sinensis is a traditional Chinese medicinal material, not a dual-use medicine, so it cannot be used as a raw material for health products.

The original issue of the Food and Drug Administration on Cordyceps can be traced back to August 2012.

In August 2012, the former State Food and Drug Administration issued the "Cattle Cordyceps sinensis for Health Food Pilot Work Program" (National Food and Drug Administration, No. 225, 2012), and for the first time standardized the use of wild cordyceps as the main raw material for health foods. , request pilot enterprise Its health food industry products have annual sales of more than 1 billion yuan. The first batch of pilot companies include Qinghai Spring, Tong Ren Tang, Kang Mei Pharmaceutical, Jinpai Brand Co., Ltd., Jiangcai Pharmaceuticals, for a period of 5 years.

However, the five-year period was not expired. On February 4, 2016, the State Food and Drug Administration issued the “General Administration's Consumer Tips on Cordyceps Products”, indicating that the recent monitoring and inspection of Cordyceps sinensis, Cordyceps sinensis powder and pure powder products showed that the The content of arsenic in Cordyceps sinensis, Cordyceps sinensis powder and pure powder tablets was 4.4 to 9.9 mg/kg.

In March 2016, the State Food and Drug Administration further released the “Notice of the General Administration of Administration on stopping the use of Cordyceps sinensis for the pilot work of health food”, announcing that the General Administration of Administration has formulated and published the “Regulations on the Registration and Filing of Health Food” in accordance with the relevant provisions of the newly revised Food Safety Law. (Decree No. 22 of the State Food and Drug Administration) The relevant declarations and approvals for health foods containing Cordyceps sinensis are carried out in accordance with the relevant provisions of the "Regulations on the Registration and Registration of Health Foods", and no production or sales are permitted without approval.

On February 27, 2018, the former State Food and Drug Administration announced that 'these 4 kinds of health products are not health care. Please don't spend money on them!' The first one is directed to Cordyceps sinensis.

When it comes to Cordyceps sinensis issued by the Food and Drug Administration on several occasions, it resembles a realistic black humor. It contains indispensable elements such as riches, spuriousness, greediness, and fragmentation.

The record of Cordyceps sinensis was first seen in the "Recovery of New Materia Medica" by Wu Yiluo, a physician.

"Cen Cao Zaixin" describes Cordyceps sinensis in this way. 'Winter is in the soil and lives like old silkworms. It is hairy. When it is unearthed in summer, it is even formed into grass. If it is not taken, it will turn into insects by winter. '

Cordyceps sinensis (alias: summer grasshopper, Cordyceps militaris, Cordyceps militaris), is a complex of the larvae of the larvae of the Cordyceps sinensis and the host of Cordyceps bat moth.

The image of Cordyceps sinensis is known as: 'The combination of moth baby and fungus'. According to public information, Cordyceps is mainly produced in Sichuan, Qinghai, Guizhou, and Yunnan, with the largest output in Sichuan, and also in Tibet and Gansu.

According to a number of ancient records, Cordyceps has nourishing effect, benefit essence gas, relieve cough and phlegm, cure phlegm and asthma, imaginary asthma, sputum, hemoptysis, spontaneous perspiration, night sweats, impotence, nocturnal emission, knee pain, long after illness No longer waiting.

Of course, modern thinking that collides with tradition does not recognize these claims.

After compositional analysis, modern science believes Cordyceps sinensis contains about 7% oxalate, 28.9% carbohydrates, about 8.4% fat, and about 25% protein. In addition, there are vitamin B12, ergosterol, hexitol, alkaloids, etc. Among them, fat also contains 82.2% of unsaturated fatty acids.

Some comments pointed out that the crude protein content of Cordyceps sinensis is less than 30% of the protein content of mushrooms. The so-called special component of Cordyceps sinensis - cordycepic acid, determined by the determination of the chemical structure, is mannitol, widely used in chewing gum, Kai Sai Lu.

With 60 years of history, Cordyceps prices rose from 1 kilogram to 6 kilograms, and to 1 kilogram (about 2,000 in terms of top level), about 180,000 yuan.

The current price of 1058 yuan/g makes the price of Cordyceps almost four times that of gold. It is said that in Tibet, which dates back to the 1960s, only 1 kilogram of Cordyceps can only exchange two packs of 3 cigarettes.

According to media reports: Since the 1990s, with the progress of scientific research, the therapeutic value of Cordyceps sinensis has been continuously developed and the price has continued to rise. The public data show that: In 1982, the price of the highest grade Cordyceps sinensis (800 grades) was approx. For 120 yuan / kg, 1993 has risen to 3,000 yuan / kg.

In the SARS era of 2003, the news of Cordyceps sinensis boosting immunity made its price reach 16,000 yuan/kg. By 2007, the price of Cordyceps sinensis reached its peak. Among them, 800 'top king grasses' were up to 200,000 at the origin. RMB/kg, the retail price delivered to the sales site reached more than RMB 420,000/kg; in 2012, the price of the finest Cordyceps sinensis listed in the Mainland had reached RMB 888,000 per kilogram, and the price rose by 7400 times in 30 years.

And behind Cordyceps, it is a drug company that is close to 100 billion market.

In August 2012, the then State Food and Drug Administration announced the trial of Cordyceps sinensis for health food products. Since this area was strictly limited to the use of this valuable medicinal material, this order was also considered to have opened this market from a policy perspective. The imagination of the foreground door.

However, for the highly qualified companies and newcomers, for the industry that is highly dependent on resources, the 'Cocktail Inventory' is a core issue that must be faced.

Public information shows that the current domestic production of Cordyceps sinensis drug , Health care products companies have more than 180.

At that time, Qinghai Spring, Kangmei Pharmaceutical, Qizheng Tibetan Medicine, Furui Group, and Tai Chi Group all increased the search for Cordyceps raw materials.

According to the data analysis of the Chisen Consulting Industry Research Center, the overall industry sales of Cordyceps sinensis grew at a compound growth rate of approximately 15% in the past five years in terms of the total output value of the industry. The industry growth mainly comes from the price increase and the increase in the proportion of deep processing. upgrade.

The research report further shows that as the application field of Cordyceps sinensis continues to expand, processing technology continues to advance, and the proportion of deep-processed products in the industry has also steadily increased. In 2009, the sales volume and sales of deep-processed products accounted for the proportion in the industry. Less than 5%, sales accounted for more than 30% of sales in 2015, sales accounted for more than 20%.

Qianxun Consulting Industry Research Center predicts that the scale of original grass sales will reach 30 billion yuan by 2020, and that of the entire Cordyceps industry will reach 75 billion yuan.

Although the General Food and Drug Administration has already made it clear that Cordyceps must be kicked out of the health care product circle, as of now, the Cordyceps market has not been significantly affected.

In fact, since May, in the A-share market, stocks involved in the concept of Cordyceps sinensis, Tai Chi Group, Pien Tze Huang, Gree Electric, Kangmei Pharmaceutical, Tibet Pharmaceutical, East China medicine , Furui shares, Tasly, Qinghai spring, Qizheng Tibetan Medicine, Guizhou Braun, Tong Ren Tang, Jiang Chinese Medicine, Kunming Pharmaceutical Group, Zuoli Pharmaceutical, Star Pharmaceutical and other 16 stocks have risen to varying degrees.

Seibu Blue found that Kangmei Pharmaceutical's 2017 annual report found that Kangmei Pharmaceutical's health products containing Cordyceps have not been affected in terms of production and sales. In addition, Kangmei expects to invest 150 million yuan in Qinghai Yushu Cordyceps Market and processing center projects. The construction stage is currently under construction.

As for many drug companies involved in the Cordyceps business, they have yet to speak out about the Cordyceps problem. There is still uncertainty about the future direction of Cordyceps and its response.